- Home
- ATRC vs BXMX Comparison
ATRC vs BXMX Comparison
Compare ATRC & BXMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRC
- BXMX
- Stock Information
- Founded
- ATRC 2000
- BXMX 2004
- Country
- ATRC United States
- BXMX United States
- Employees
- ATRC N/A
- BXMX N/A
- Industry
- ATRC Medical/Dental Instruments
- BXMX Investment Managers
- Sector
- ATRC Health Care
- BXMX Finance
- Exchange
- ATRC Nasdaq
- BXMX Nasdaq
- Market Cap
- ATRC 1.5B
- BXMX 1.5B
- IPO Year
- ATRC 2005
- BXMX N/A
- Fundamental
- Price
- ATRC $33.75
- BXMX $12.70
- Analyst Decision
- ATRC Strong Buy
- BXMX
- Analyst Count
- ATRC 10
- BXMX 0
- Target Price
- ATRC $48.50
- BXMX N/A
- AVG Volume (30 Days)
- ATRC 481.1K
- BXMX 205.6K
- Earning Date
- ATRC 04-29-2025
- BXMX 01-01-0001
- Dividend Yield
- ATRC N/A
- BXMX 7.24%
- EPS Growth
- ATRC N/A
- BXMX N/A
- EPS
- ATRC N/A
- BXMX N/A
- Revenue
- ATRC $465,307,000.00
- BXMX N/A
- Revenue This Year
- ATRC $14.60
- BXMX N/A
- Revenue Next Year
- ATRC $12.58
- BXMX N/A
- P/E Ratio
- ATRC N/A
- BXMX N/A
- Revenue Growth
- ATRC 16.55
- BXMX N/A
- 52 Week Low
- ATRC $18.94
- BXMX $11.75
- 52 Week High
- ATRC $43.11
- BXMX $13.75
- Technical
- Relative Strength Index (RSI)
- ATRC 53.13
- BXMX 49.80
- Support Level
- ATRC $30.78
- BXMX $12.00
- Resistance Level
- ATRC $34.23
- BXMX $12.75
- Average True Range (ATR)
- ATRC 1.97
- BXMX 0.43
- MACD
- ATRC 0.28
- BXMX 0.05
- Stochastic Oscillator
- ATRC 88.41
- BXMX 94.16
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.
About BXMX Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest
Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options strategy of writing (selling) index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.